Literature DB >> 23487450

tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Raabya Rossenkhan1, Iain J MacLeod, Theresa K Sebunya, Eduardo Castro-Nallar, Mary Fran McLane, Rosemary Musonda, Berhanu A Gashe, Vlad Novitsky, M Essex.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Tat is a mediator of viral transcription and is involved in the control of virus replication. However, associations between HIV-1 Tat diversity and functional effects during primary HIV-1 infection are still unclear. We estimated selection pressures in tat exon 1 using the mixed-effects model of evolution with 672 viral sequences generated from 20 patients infected with HIV-1 subtype C (HIV-1C) over 500 days postseroconversion. tat exon 1 residues 3, 4, 21, 24, 29, 39, and 68 were under positive selection, and we established that specific amino acid signature patterns were apparent in primary HIV-1C infection compared with chronic infection. We assessed the impact of these mutations on long terminal repeat (LTR) activity and found that Tat activity was negatively affected by the Ala(21) substitution identified in 13/20 (65%) of patients, which reduced LTR activity by 88% (± 1%) (P < 0.001). The greatest increase in Tat activity was seen with the Gln(35)/Lys(39) double mutant that resulted in an additional 49% (± 14%) production of LTR-driven luciferase (P = 0.012). There was a moderate positive correlation between Tat-mediated LTR activity and HIV-1 RNA in plasma (P = 0.026; r = 0.400) after 180 days postseroconversion that was reduced by 500 days postseroconversion (P = 0.043; r = 0.266). Although Tat activation of the LTR is not a strong predictor of these clinical variables, there are significant linear relationships between Tat transactivation and patients' plasma viral loads and CD4 counts, highlighting the complex interplay between Tat mutations in early HIV-1C infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23487450      PMCID: PMC3648179          DOI: 10.1128/JVI.03297-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  95 in total

1.  Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.

Authors:  Philippe Roof; Maria Ricci; Pierre Genin; Monty A Montano; Max Essex; Mark A Wainberg; Anne Gatignol; John Hiscott
Journal:  Virology       Date:  2002-04-25       Impact factor: 3.616

2.  Acetylation of the HIV-1 Tat protein: an in vitro study.

Authors:  Wilma Dormeyer; Alexander Dorr; Melanie Ott; Martina Schnölzer
Journal:  Anal Bioanal Chem       Date:  2003-07-09       Impact factor: 4.142

3.  HIV quasispecies and resampling.

Authors:  S L Liu; A G Rodrigo; R Shankarappa; G H Learn; L Hsu; O Davidov; L P Zhao; J I Mullins
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

4.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

5.  An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection.

Authors:  Stephen M Smith; Sara Pentlicky; Zachary Klase; Mahender Singh; Christine Neuveut; Chun-yi Lu; Marvin S Reitz; Robert Yarchoan; Preston A Marx; Kuan-Teh Jeang
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

6.  Identification of primary HIV-1C infection in Botswana.

Authors:  V Novitsky; E Woldegabriel; C Wester; E McDonald; R Rossenkhan; M Ketunuti; J Makhema; G R Seage; M Essex
Journal:  AIDS Care       Date:  2008-08

7.  IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis.

Authors:  V Fiorelli; G Barillari; E Toschi; C Sgadari; P Monini; M Stürzl; B Ensoli
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

8.  Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.

Authors:  Jesus F Salazar-Gonzalez; Elizabeth Bailes; Kimmy T Pham; Maria G Salazar; M Brad Guffey; Brandon F Keele; Cynthia A Derdeyn; Paul Farmer; Eric Hunter; Susan Allen; Olivier Manigart; Joseph Mulenga; Jeffrey A Anderson; Ronald Swanstrom; Barton F Haynes; Gayathri S Athreya; Bette T M Korber; Paul M Sharp; George M Shaw; Beatrice H Hahn
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

9.  Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection.

Authors:  Raabya Rossenkhan; Vladimir Novitsky; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; M Essex
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

Review 10.  What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

Authors:  Grant R Campbell; Erwann P Loret
Journal:  Retrovirology       Date:  2009-05-25       Impact factor: 4.602

View more
  9 in total

1.  The Evolving Profile of the Signature Amino Acid Residues in HIV-1 Subtype C Tat.

Authors:  Shambhu Prasad G Aralaguppe; Shilpee Sharma; Malini Menon; Vinayaka R Prasad; Shanmugam Saravanan; Kailapuri G Murugavel; Suniti Solomon; Udaykumar Ranga
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02-09       Impact factor: 2.205

Review 2.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

3.  Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.

Authors:  Andrey K Shevchenko; Daria V Zhernakova; Sergey V Malov; Alexey Komissarov; Sofia M Kolchanova; Gaik Tamazian; Alexey Antonik; Nikolay Cherkasov; Sergey Kliver; Anastasiia Turenko; Mikhail Rotkevich; Igor Evsyukov; David Vlahov; Prisca K Thami; Simani Gaseitsiwe; Vladimir Novitsky; Myron Essex; Stephen J O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 12.779

4.  HIV-1 subtype C Tat exon-1 amino acid residue 24K is a signature for neurocognitive impairment.

Authors:  Vurayai Ruhanya; Graeme Brendon Jacobs; Robert H Paul; John A Joska; Soraya Seedat; George Nyandoro; Richard H Glashoff; Susan Engelbrecht
Journal:  J Neurovirol       Date:  2022-04-08       Impact factor: 3.739

5.  Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.

Authors:  Diego Pandeló José; Koen Bartholomeeusen; Rodrigo Delvecchio da Cunha; Celina Monteiro Abreu; Jan Glinski; Thais Barbizan Ferreira da Costa; Ana Flávia Mello Bacchi Rabay; Luiz Francisco Pianowski Filho; Lech W Dudycz; Udaykumar Ranga; Boris Matija Peterlin; Luiz Francisco Pianowski; Amilcar Tanuri; Renato Santana Aguiar
Journal:  Virology       Date:  2014-07-09       Impact factor: 3.616

6.  Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants.

Authors:  Bernard S Bagaya; José F Vega; Meijuan Tian; Gabrielle C Nickel; Yuejin Li; Kendall C Krebs; Eric J Arts; Yong Gao
Journal:  Retrovirology       Date:  2015-05-23       Impact factor: 4.602

7.  PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.

Authors:  Iain J MacLeod; Christopher F Rowley; M Essex
Journal:  Commun Biol       Date:  2021-02-18

8.  Molecular characterization of full-length Tat in HIV-1 subtypes B and C.

Authors:  Chandra Nath Roy; Irona Khandaker; Yuki Furuse; Hitoshi Oshitani
Journal:  Bioinformation       Date:  2015-03-31

Review 9.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.